ISRCTN21587955已完成不适用
Randomised trial of adjuvant therapy in operable pancreatic cancer
Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically proven adenocarcinoma of the pancreas, macroscopically resected. (Patients with pancreatic cystadenocarcinoma and endocrine tumours, tumours of the pancreas and tumours of the duodenum, ampulla of Vater and lower common bile duct are excluded).
- •2. No evidence of ascities, metastases to the liver, spread to other distant abdominal organs, peritoneal or omental seedlings, or distant metastases
- •3. Fully recovered from the operation, fit to take part in the trial and life expectancy of more than 3 months
- •4. No previous or concurrent malignancy diagnosed, except basal cell carcinoma of skin or carcinoma in situ of cervix
- •5. No serious medical or psychological condition precluding adjuvant treatment
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
不适用
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high risk of relapse based on the Pervenio? Lung RS AssayCompletely resected stage I non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2013-001494-24-ESEncore Clinical, Inc1,050
进行中（未招募）
1 期
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029517Term: Non-small cell lung cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001494-24-FRIFCT1,050
招募中
1 期
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lungcancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code: 10025050Term: Lung cancer non-small cell stage I Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025051Term: Lung cancer non-small cell stage II Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025044Term: Lung cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104CTIS2024-511185-37-00Razor Genomics Inc.915
进行中（未招募）
1 期
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2013-001494-24-DERazor Genomics, Inc.1,050
尚未招募
2 期
Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observatioNL-OMON50102niversity Hospital Essen30